Literature DB >> 10516049

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

H F Günthard1, S D Frost, A J Leigh-Brown, C C Ignacio, K Kee, A S Perelson, C A Spina, D V Havlir, M Hezareh, D J Looney, D D Richman, J K Wong.   

Abstract

In human immunodeficiency virus (HIV)-infected patients treated with potent antiretroviral therapy, the persistence of latently infected cells may reflect the long decay half-life of this cellular reservoir or ongoing viral replication at low levels with continuous replenishment of the population or both. To address these possibilities, sequences encompassing the C2 and V3 domains of HIV-1 env were analyzed from virus present in baseline plasma and from viral isolates obtained after 2 years of suppressive therapy in six patients. The presence of sequence changes consistent with evolution was demonstrated for three subjects and correlated with less complete suppression of viral replication, as indicated by the rapidity of the initial virus load decline or the intermittent reappearance of even low levels of detectable viremia. Together, these results provide evidence for ongoing replication. In the remaining three patients, virus recovered after 2 years of therapy was either genotypically contemporary with or ancestral to virus present in plasma 2 years before, indicating that virus recovery had indeed resulted from activation of latently infected cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516049      PMCID: PMC112975     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro.

Authors:  S Delassus; R Cheynier; S Wain-Hobson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Variances of the average numbers of nucleotide substitutions within and between populations.

Authors:  M Nei; L Jin
Journal:  Mol Biol Evol       Date:  1989-05       Impact factor: 16.240

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Evolutionary relationship of DNA sequences in finite populations.

Authors:  F Tajima
Journal:  Genetics       Date:  1983-10       Impact factor: 4.562

5.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.

Authors:  P Simmonds; P Balfe; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

7.  Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations.

Authors:  P Balfe; P Simmonds; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

8.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.

Authors:  P Simmonds; L Q Zhang; F McOmish; P Balfe; C A Ludlam; A J Brown
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

Authors:  J J de Jong; J Goudsmit; W Keulen; B Klaver; W Krone; M Tersmette; A de Ronde
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Extensive variation of human immunodeficiency virus type-1 in vivo.

Authors:  M S Saag; B H Hahn; J Gibbons; Y Li; E S Parks; W P Parks; G M Shaw
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

View more
  64 in total

1.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

Review 2.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

4.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

5.  Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.

Authors:  Tuofu Zhu; David Muthui; Sarah Holte; David Nickle; Feng Feng; Scott Brodie; Yon Hwangbo; James I Mullins; Lawrence Corey
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.

Authors:  Silvia Baroncelli; Maria Franca Pirillo; Clementina Maria Galluzzo; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Gabriella d'Ettorre; Daniela Segala; Angela Vivarelli; Federica Sozio; Oscar Cirioni; Liliana Elena Weimer; Vincenzo Fragola; Giustino Parruti; Marco Floridia
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

8.  Detection of YMDD mutants using universal template real-time PCR.

Authors:  Rong-Sheng Wang; Hua Zhang; Yu-Fen Zhu; Bei Han; Zhi-Jun Yang
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.

Authors:  Carlos A Lopez; Manuel Vazquez; Martin D Hill; Maria Del C Colon; Tirtsa Porrata-Doria; Ian C D Johnston; Eric Lorenzo
Journal:  Arch Virol       Date:  2010-04-23       Impact factor: 2.574

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.